[PROBLEMS] To provide a compound which is useful as an inhibitor of the kinaseactivity of an EML4-ALK fusion protein and an EGFR variant protein. [MEANS FORSOLVING PROBLEMS] As the results of intensive studies on a compound having aneffect of inhibiting the kinase activity of an EML4-ALK fusion protein and a EGFRvariant protein, it has been found out that a di(arylamino)aryl compound hasan activity of inhibiting the kinase activity of an EML4-ALK fusion protein anda EGFR variant protein. The above-described compound can be used as a medicinalcomposition for preventing and/or treating cancer, pulmonary cancer, non-small-cellpulmonary cancer, small-cell pulmonary cancer, EML4-ALK fusion polynucleotidepositive and/or EGFR variant polynucleotide positive cancer, EML4-ALK fusionpolynucleotide positive and/or EGFR variant polynucleotide positive pulmonarycancer, EML4-ALK fusion polynucleotide positive and/or EGFR variant polynucleotidepositive non-small-cell pulmonary cancer, or the like.
